The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 09, 2017
Filed:
Oct. 27, 2015
Applicant:
Oculus Innovative Sciences, Inc., Petaluma, CA (US);
Inventor:
Hojabr Alimi, Santa Rosa, CA (US);
Assignee:
SONOMA PHARMACEUTICALS, INC., Petaluma, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 33/00 (2006.01); A61K 33/20 (2006.01); A61K 45/06 (2006.01); A61K 47/32 (2006.01); A61L 2/22 (2006.01); A01N 59/00 (2006.01); A61K 9/00 (2006.01); A61L 2/00 (2006.01); A61L 2/18 (2006.01); C02F 1/461 (2006.01); C02F 1/467 (2006.01); A61L 2/03 (2006.01); C02F 1/72 (2006.01); C02F 1/76 (2006.01); C02F 103/02 (2006.01);
U.S. Cl.
CPC ...
A61K 33/20 (2013.01); A01N 59/00 (2013.01); A61K 9/007 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 33/00 (2013.01); A61K 45/06 (2013.01); A61K 47/32 (2013.01); A61L 2/0088 (2013.01); A61L 2/186 (2013.01); C02F 1/4618 (2013.01); C02F 1/4672 (2013.01); A61L 2/035 (2013.01); A61L 2/22 (2013.01); A61L 2202/11 (2013.01); A61L 2202/122 (2013.01); A61L 2202/17 (2013.01); A61L 2202/24 (2013.01); C02F 1/4674 (2013.01); C02F 1/722 (2013.01); C02F 1/76 (2013.01); C02F 2001/46195 (2013.01); C02F 2103/026 (2013.01); C02F 2201/4618 (2013.01); C02F 2201/46115 (2013.01); C02F 2209/04 (2013.01); C02F 2209/06 (2013.01); C02F 2209/40 (2013.01); C02F 2303/04 (2013.01);
Abstract
Provided is a method for preventing or treating sinusitis by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers. The ORP water solution can be administered alone or, e.g., in combination with one or more additional therapeutic agents.